Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

genepharm s.a, greece - exemestane - film-coated tablet - 25 mg

Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

genepharm s.a, greece - exemestane - film-coated tablet - 25 mg

Spojené státy - angličtina - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane tablets are indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)] . exemestane tablets are indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. based on findings in animal studies and its mechanism of action, exemestane tablets can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased inc

Spojené státy - angličtina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-feta

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - exemestane - oral tablet - 25mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 20mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cp pharmaceuticals ltd. - tamoxifen (tamoxifen citrate) - tablets film-coated - 10mg

Singapur - angličtina - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - ribociclib succinate 254.4mg eqv ribociclib - tablet, film coated - ribociclib succinate 254.4mg eqv ribociclib 200mg

Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - exemestane 25 mg - film-coated tablet - 25 mg - exemestane 25 mg - exemestane

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

beacon pharmaceuticals ltd - exemestane - oral tablet - 25mg